Lilly to Acquire AtaiBeckley in Up to $3.8bn Deal to Expand into Psychedelic Depression Therapies

Acquisition gives Lilly late-stage psychedelic pipeline targeting treatment-resistant depression and major psychiatric disorders Eli Lilly has agreed to acquire AtaiBeckley in a deal worth up to $3.8 billion, marking the pharmaceutical giant's entry into the rapidly evolving psychedelic therapeutics market.

The acquisition strengthens Lilly's neuroscience portfolio with a pipeline of late-stage psychedelic-based therapies aimed at treatment-resistant depression (TRD), major depressive disorder (MDD) and other difficult-to-treat psychiatric conditions.

The transaction is expected to close during the third quarter of 2026.

Lilly Expands Neuroscience Portfolio Through AtaiBeckley Acquisition

Under the agreement, Lilly will acquire all outstanding shares of AtaiBeckley for $6.75 per share in cash, valuing the company at approximately $2.8 billion.

Shareholders will also be eligible to receive a contingent value right (CVR) worth $2.50 per share, representing around $1 billion in additional milestone payments linked to the clinical and regulatory progress of the company's lead psychedelic programmes.

The acquisition follows months of industry speculation that Lilly was evaluating opportunities within the psychedelic medicine sector.

BPL-003 Leads AtaiBeckley's Psychedelic Pipeline

The centrepiece of the acquisition is BPL-003, an intranasal formulation of mebufotenin benzoate currently being developed for treatment-resistant depression.

The therapy recently achieved both primary and secondary endpoints in a Phase IIb clinical trial, with a global Phase III programme already underway.

Lilly will also acquire VLS-01, an oral transmucosal film formulation of N,N-Dimethyltryptamine (DMT), which is expected to enter late-stage clinical development for major depressive disorder.

A third pipeline candidate, EMP-01, is an oral formulation of R-MDMA being investigated as a treatment for social anxiety disorder.

Together, the portfolio provides Lilly with multiple late-stage assets targeting significant unmet needs across psychiatry.

Psychedelic Medicines Continue to Gain Pharmaceutical Momentum

The acquisition reflects growing pharmaceutical confidence in psychedelic-based medicines as a new generation of treatments for neuropsychiatric disorders.

Interest in the sector has accelerated following the commercial success of Johnson & Johnson's Spravato (esketamine), while several other companies continue advancing psychedelic therapies through late-stage development.

Industry momentum has also been supported by regulatory initiatives designed to accelerate the development of innovative treatments for severe mental health conditions.

Why the Deal Matters

Treatment-resistant depression remains one of the largest unmet needs in mental healthcare, with many patients failing to respond adequately to conventional antidepressants.

Rapid-acting psychedelic therapies are being investigated as potential alternatives capable of producing faster and more durable clinical responses through novel mechanisms of action.

By acquiring AtaiBeckley, Lilly gains immediate access to a differentiated pipeline without the lengthy timelines associated with early-stage drug discovery.

The transaction also expands Lilly's position in neuroscience beyond traditional psychiatric medicines into one of the fastest-growing areas of pharmaceutical innovation.

Executive Commentary

Lilly Neuroscience President Carole Ho said the acquisition reflects the company's commitment to addressing difficult-to-treat mental health conditions.

"Treatment-resistant depression persists even after multiple treatments have failed. Advancing AtaiBeckley's investigational therapies gives us a real chance to change that."

Analysts have also highlighted the strategic importance of the acquisition, noting that the deal broadens Lilly's neuroscience portfolio while positioning the company at the forefront of next-generation psychiatric drug development.

Outlook

The acquisition represents another significant vote of confidence in psychedelic therapeutics from a major pharmaceutical company.

With BPL-003 already entering Phase III development and additional candidates progressing towards late-stage studies, Lilly is positioning itself to become a major player in the future treatment landscape for depression and other serious psychiatric disorders.

As clinical evidence continues to mature, the deal highlights how large pharmaceutical companies are increasingly turning to innovative neuroscience platforms to address some of the most challenging areas of medicine.

---

Discover how nuaxia can support your next medical education initiative:

• Find out more about our specialist services - Moore's Outcome Assessments, Educational Needs Assessments and Patient Impact Studies for the Medical Education sector 

• Contact us on: support@nuaxia.com